The data from two studies on about 2,707 individuals aged 12 to 17 years show Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, said Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII.
The antibody level of the Corbe vax Covid-19 vaccine is very high and overall it is a very useful vaccine, says Dr NK Arora, Chairman of Covid-19 Working Group of NTAGI.
This approval for Corbevax is likely to speed up the ongoing vaccination drive for children between 15 and 18 years of age, and also for those between 12 and 14 years of age. However, the approval is subject to certain conditions.
Only a small fraction of children hospitalized for COVID-19 have been fully vaccinated, according to a report released Thursday from the Centers for Disease Control and Prevention (CDC).